Back to Search
Start Over
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia.
- Source :
-
Annals of Oncology . Sep2024, Vol. 35 Issue 9, p762-768. 7p. - Publication Year :
- 2024
-
Abstract
- • The update covers the approval of time-limited ibrutinib–venetoclax in first line and new data on MRD-driven treatment. • It also covers the approval of the BTKi zanubrutinib in both treatment-naive and relapsed or refractory CLL. • Additional evidence on the time-limited combination of venetoclax plus an anti-CD20 antibody in the first line are included. • Options for later-line treatments based on the type of prior lines of treatment are also included. • Recommendations are based on available scientific data and the authors' collective expert opinion. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 35
- Issue :
- 9
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 179276378
- Full Text :
- https://doi.org/10.1016/j.annonc.2024.06.016